Robert Day

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1496372/publications.pdf

Version: 2024-02-01

63	2,642	159585	189892
papers	citations	30 h-index	50 g-index

65	65	65	2863
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	PACE4-altCT isoform of proprotein convertase PACE4 as tissue and plasmatic biomarker for prostate cancer. Scientific Reports, 2022, 12, 6066.	3.3	4
2	Design and Structureâ€“Activity Relationship of a Potent Furin Inhibitor Derived from Influenza Hemagglutinin. ACS Medicinal Chemistry Letters, 2021, 12, 365-372.	2.8	7
3	Mast Cell Degranulation Increases Mouse Mast Cell Protease 4â€“Dependent Vasopressor Responses to Big Endothelin-1 But Not Angiotensin I. Journal of Pharmacology and Experimental Therapeutics, 2021, 376, 213-221.	2.5	3
4	Functional analysis of natural <scp>PCSK</scp>9 mutants in modern and archaic humans. FEBS Journal, 2020, 287, 515-528.	4.7	8
5	Upregulation of PACE4 in prostate cancer is not dependent on E2F transcription factors. Canadian Journal of Physiology and Pharmacology, 2020, 98, 477-481.	1.4	3
6	Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (Family With) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.4	36
7	Enhanced anti-tumor activity of the Multi-Leu peptide PACE4 inhibitor transformed into an albumin-bound tumor-targeting prodrug. Scientific Reports, 2019, 9, 2118.	3.3	11
8	V-ATPase-associated prorenin receptor is upregulated in prostate cancer after PTEN loss. Oncotarget, 2019, 10, 4923-4936.	1.8	12
9	Improving the Selectivity of PACE4 Inhibitors through Modifications of the P1 Residue. Journal of Medicinal Chemistry, 2018, 61, 11250-11260.	6.4	6
10	Mouse Mast Cell Protease 4 Deletion Protects Heart Function and Survival After Permanent Myocardial Infarction. Frontiers in Pharmacology, 2018, 9, 868.	3.5	12
11	Evaluation of PACE4 isoforms as biomarkers in thyroid cancer. Journal of Otolaryngology - Head and Neck Surgery, 2018, 47, 63.	1.9	9
12	Increasing C-Terminal Hydrophobicity Improves the Cell Permeability and Antiproliferative Activity of PACE4 Inhibitors against Prostate Cancer Cell Lines. Journal of Medicinal Chemistry, 2018, 61, 8457-8467.	6.4	4
13	Thrombin activation of protein C requires prior processing by a liver proprotein convertase. Journal of Biological Chemistry, 2017, 292, 10564-10573.	3.4	10
14	Macrocyclization of a potent PACE4 inhibitor: Benefits and limitations. European Journal of Cell Biology, 2017, 96, 476-485.	3.6	7
15	PACE4 is an important driver of ZR-75-1 estrogen receptor-positive breast cancer proliferation and tumor progression. European Journal of Cell Biology, 2017, 96, 469-475.	3.6	14
16	Positional Scanning Identifies the Molecular Determinants of a High Affinity Multi-Leucine Inhibitor for Furin and PACE4. Journal of Medicinal Chemistry, 2017, 60, 2732-2744.	6.4	9
17	PACE4 Undergoes an Oncogenic Alternative Splicing Switch in Cancer. Cancer Research, 2017, 77, 6863-6879.	0.9	58
18	Rational Design of a Highly Potent and Selective Peptide Inhibitor of PACE4 by Salt Bridge Interaction with D160 at Position P3. ChemMedChem, 2017, 12, 1169-1172.	3.2	9

#	Article	IF	Citations
19	Novel Insights into Structureâ€“Activity Relationships of Nâ€Terminally Modified PACE4 Inhibitors. ChemMedChem, 2016, 11, 289-301.	3.2	12
20	An Unbiased Mass Spectrometry Approach Identifies Glypican-3 as an Interactor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR) in Hepatocellular Carcinoma Cells. Journal of Biological Chemistry, 2016, 291, 24676-24687.	3.4	14
21	Multi-Leu PACE4 Inhibitor Retention within Cells Is PACE4 Dependent and a Prerequisite for Antiproliferative Activity. BioMed Research International, 2015, 2015, 1-9.	1.9	5
22	Therapeutic uses of furin and its inhibitors: a patent review. Expert Opinion on Therapeutic Patents, 2015, 25, 379-396.	5.0	70
23	Chymase inhibitor-sensitive synthesis of endothelin-1 (1â€“31) by recombinant mouse mast cell protease 4 and human chymase. Biochemical Pharmacology, 2015, 94, 91-100.	4.4	18
24	PACE4 inhibitors and their peptidomimetic analogs block prostate cancer tumor progression through quiescence induction, increased apoptosis and impaired neovascularisation. Oncotarget, 2015, 6, 3680-3693.	1.8	35
25	PACE4-Based Molecular Targeting of Prostate Cancer Using an Engineered 64Cu-Radiolabeled Peptide Inhibitor. Neoplasia, 2014, 16, 634-643.	5.3	14
26	Design, Synthesis, and Structureâ€“Activity Relationship Studies of a Potent PACE4 Inhibitor. Journal of Medicinal Chemistry, 2014, 57, 98-109.	6.4	30
27	Optimization of Furin Inhibitors To Protect against the Activation of Influenza Hemagglutinin H5 and Shiga Toxin. Journal of Medicinal Chemistry, 2014, 57, 29-41.	6.4	24
28	Implications of Proprotein Convertases in Ovarian Cancer Cell Proliferation and Tumor Progression: Insights for PACE4 as a Therapeutic Target. Translational Oncology, 2014, 7, 410-419.	3.7	30
29	Annexin A2 Reduces PCSK9 Protein Levels via a Translational Mechanism and Interacts with the M1 and M2 Domains of PCSK9. Journal of Biological Chemistry, 2014, 289, 17732-17746.	3.4	40
30	Knockdown Strategies for the Study of Proprotein Convertases and Proliferation in Prostate Cancer Cells. Methods in Molecular Biology, 2014, 1103, 67-82.	0.9	6
31	Proteomic analyses of serous and endometrioid epithelial ovarian cancers â€“ Cases studies â€“ Molecular insights of a possible histological etiology of serous ovarian cancer. Proteomics - Clinical Applications, 2013, 7, 337-354.	1.6	18
32	Disruption of Proprotein Convertase 1/3 (PC1/3) Expression in Mice Causes Innate Immune Defects and Uncontrolled Cytokine Secretion. Journal of Biological Chemistry, 2012, 287, 14703-14717.	3.4	32
33	The M2 Module of the Cys-His-rich Domain (CHRD) of PCSK9 Protein Is Needed for the Extracellular Low-density Lipoprotein Receptor (LDLR) Degradation Pathway. Journal of Biological Chemistry, 2012, 287, 43492-43501.	3.4	62
34	The Multi-Leu Peptide Inhibitor Discriminates Between PACE4 and Furin And Exhibits Antiproliferative Effects On Prostate Cancer Cells. Journal of Medicinal Chemistry, 2012, 55, 10501-10511.	6.4	49
35	Highly Potent Inhibitors of Proprotein Convertase Furin as Potential Drugs for Treatment of Infectious Diseases. Journal of Biological Chemistry, 2012, 287, 21992-22003.	3.4	98
36	Role of Proprotein Convertases in Prostate Cancer Progression. Neoplasia, 2012, 14, 1032-IN6.	5.3	52

#	Article	IF	Citations
37	Ovarian cancer molecular pathology. Cancer and Metastasis Reviews, 2012, 31, 713-732.	5.9	57
38	The C-terminal fragment of the immunoproteasome PA28S (Reg alpha) as an early diagnosis and tumor-relapse biomarker: evidence from mass spectrometry profiling. Histochemistry and Cell Biology, 2012, 138, 141-154.	1.7	29
39	Molecular Validation of PACE4 as a Target in Prostate Cancer. Translational Oncology, 2011, 4, 157-IN9.	3.7	67
40	On the cutting edge of proprotein convertase pharmacology: from molecular concepts to clinical applications. Biomolecular Concepts, 2011, 2, 421-438.	2.2	57
41	Proteolytic Processing of Angiopoietin-like Protein 4 by Proprotein Convertases Modulates Its Inhibitory Effects on Lipoprotein Lipase Activity. Journal of Biological Chemistry, 2011, 286, 15747-15756.	3.4	116
42	Analysis of peptides in prohormone convertase 1/3 null mouse brain using quantitative peptidomics. Journal of Neurochemistry, 2010, 114, 215-225.	3.9	66
43	Potent Inhibitors of Furin and Furin-like Proprotein Convertases Containing Decarboxylated P1 Arginine Mimetics. Journal of Medicinal Chemistry, 2010, 53, 1067-1075.	6.4	111
44	Selective and potent furin inhibitors protect cells from anthrax without significant toxicity. International Journal of Biochemistry and Cell Biology, 2010, 42, 987-995.	2.8	36
45	MALDI imaging mass spectrometry in ovarian cancer for tracking, identifying, and validating biomarkers. Medical Science Monitor, 2010, 16, BR233-45.	1.1	60
46	Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation. Journal of Biological Chemistry, 2009, 284, 28856-28864.	3.4	228
47	Inhibition of Furin/Proprotein Convertase-catalyzed Surface and Intracellular Processing by Small Molecules. Journal of Biological Chemistry, 2009, 284, 15729-15738.	3.4	65
48	Substrate Cleavage Analysis of Furin and Related Proprotein Convertases. Journal of Biological Chemistry, 2008, 283, 20897-20906.	3.4	126
49	Targeting Host Cell Furin Proprotein Convertases as a Therapeutic Strategy against Bacterial Toxins and Viral Pathogens*. Journal of Biological Chemistry, 2007, 282, 20847-20853.	3.4	93
50	Short Polybasic Peptide Sequences Are Potent Inhibitors of PC5/6 and PC7: Use of Positional Scanning-Synthetic Peptide Combinatorial Libraries as a Tool for the Optimization of Inhibitory Sequences. Molecular Pharmacology, 2007, 71, 323-332.	2.3	59
51	Cutting back on pro-protein convertases: the latest approaches to pharmacological inhibition. Trends in Pharmacological Sciences, 2005, 26, 294-301.	8.7	115
52	Secretory granule biogenesis and chromogranin A: master gene, on/off switch or assembly factor?. Trends in Endocrinology and Metabolism, 2003, 14, 10-13.	7.1	64
53	Furin Processing and Proteolytic Activation of Semliki Forest Virus. Journal of Virology, 2003, 77, 2981-2989.	3.4	82
54	Inhibitory Potency and Specificity of Subtilase-like Pro-protein Convertase (SPC) Prodomains. Journal of Biological Chemistry, 2002, 277, 7648-7656.	3.4	83

#	Article	IF	Citations
55	Inhibitors of the Subtilase-Like Pro-Protein Convertases (SPCs). Current Pharmaceutical Design, 2002, 8, 549-562.	1.9	27
56	The neuroendocrine phenotype, cellular plasticity, and the search for genetic switches: redefining the diffuse neuroendocrine system. Neuroendocrinology Letters, 2002, 23, 447-51.	0.2	20
57	IDA-1, aCaenorhabditis elegans homolog of the diabetic autoantigens IA-2 and phogrin, is expressed in peptidergic neurons in the worm. Journal of Comparative Neurology, 2001, 429, 127-143.	1.6	69
58	Comparative Characterization of Two Forms of Recombinant Human SPC1 Secreted from Schneider 2 Cells. Protein Expression and Purification, 2000, 19, 113-124.	1.3	20
59	The distinct gene expression of the pro-hormone convertases in the rat heart suggests potential substrates. Cell and Tissue Research, 1995, 279, 539-549.	2.9	58
60	Protease inhibitors suppress in vitro growth of human small cell lung cancer. Peptides, 1993, 14, 1021-1028.	2.4	21
61	Asbestos-Induced Fibrosis in Rats: Increase in Lung Mast Cells and Autacoid Contents. Experimental Lung Research, 1987, 13, 311-327.	1.2	31
62	Dynorphin in bovine adrenal medulla. International Journal of Peptide and Protein Research, 1982, 19, 10-17.	0.1	25
63	Dynorphin in bovine adrenal medulla. International Journal of Peptide and Protein Research, 1982, 19, 18-24.	0.1	24